



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/395		A3	(11) International Publication Number: WO 98/44948
			(43) International Publication Date: 15 October 1998 (15.10.98)
(21) International Application Number: PCT/CA98/00325		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 7 April 1998 (07.04.98)			
(30) Priority Data: 60/041,921 7 April 1997 (07.04.97) US			
(71) Applicant (for all designated States except US): CANGENE CORPORATION [CA/CA]; 104 Chancellor Matheson Road, Winnipeg, Manitoba R3T 2N2 (CA).			
(72) Inventors; and		Published	
(75) Inventors/Applicants (for US only): PRICE, Hugh, W. [CA/CA]; 350 Kingston Crescent, Winnipeg, Manitoba R2M 0T8 (CA). WOLOSKI, B., Michael, R. [CA/CA]; Cangene Corporation, 104 Chancellor Matheson, Winnipeg, Manitoba R3T 2N2 (CA).		With international search report. With amended claims.	
(74) Agent: BERESKIN & PARR; 40th floor, 40 King Street West, Toronto, Ontario M5H 3Y2 (CA).		(88) Date of publication of the international search report: 11 February 1999 (11.02.99)	
		Date of publication of the amended claims: 1 April 1999 (01.04.99)	

(54) Title: INTRAVENOUS IMMUNE GLOBULIN FORMULATION CONTAINING A NON-IONIC SURFACE ACTIVE AGENT WITH IMPROVED PHARMACOKINETIC PROPERTIES

(57) Abstract

Addition of a non-ionic surface active agent to an immune globulin formulation extends the serum half-life of relatively pure and non-aggregated immune globulin suitable for intravenous injection or infusion. The non-ionic surface active agent may be a sorbitan ester or a polyoxyethylene sorbitan ester of a fatty acid. Formulations of the present invention is therapeutically advantageous over conventional formulations in that an extended serum half-life of the immune globulin improves its therapeutic effectiveness, reduces the frequency of drug administration and/or lowers the therapeutic effective dosage required and cost of treatment.

